The Evidence Behind Flore
Flore's formulation intelligence is grounded in real-world data from our own cohorts and in published, peer-reviewed research. What follows is what we've observed and the studies behind the rationale. This is real-world evidence — observational, uncontrolled, and largely self-reported. No statement here is a disease claim.
Systems
Real-world outcomes (self-reported)Across our paired real-world cohort (n=651), 47.4% of tracked symptom-instances resolved over the course of personalized formulation, and in our separate tolerability cohort (n=18,383) 95.1% of customers remained complaint-free. This is observational, self-reported real-world evidence — not a controlled trial, and not a disease claim.
Gastrointestinal The Regular One
Strains: Bifidobacterium animalis ssp. lactis + Bifidobacterium longum
Rationale (mechanistic, not measured)Bifidobacterium fermentation of fiber to short-chain fatty acids supports motility and mucosal-barrier integrity.
Study: Martoni CJ, et al. Impact of a probiotic product on bowel habits in functional constipation. J Dig Dis. 2019;20(9):478–487. PMID 31271261. pubmed.ncbi.nlm.nih.gov/31271261
Mood / Neurological The Bright One
Strains: Bifidobacterium animalis ssp. lactis + Lactiplantibacillus plantarum
Rationale (mechanistic, not measured)Gut–brain-axis modulation of tryptophan metabolism and vagal signaling.
Study: Hidalgo-Cantabrana C, et al. Lactiplantibacillus plantarum HEAL9 improves cognition in moderately stressed subjects. Nutrients. 2023;15(15):3466. PMID 37571403. pubmed.ncbi.nlm.nih.gov/37571403
Joint / Musculoskeletal The Mighty One
Strains: Bifidobacterium animalis ssp. lactis + Bifidobacterium bifidum
Rationale (mechanistic, not measured)Anti-inflammatory rationale matching the observed arthritis/fibromyalgia signal.
Immune The Strong One
Strains: Lactobacillus acidophilus + Bifidobacterium longum
Rationale (mechanistic, not measured)GALT priming and secretory-IgA support.
Study: Leyer GJ, et al. Probiotic effects on cold and influenza-like symptom incidence in children. Pediatrics. 2009;124(2):e172–179. PMID 19651563. pubmed.ncbi.nlm.nih.gov/19651563
Skin The Clear One
Strains: Lactobacillus salivarius + Bifidobacterium animalis ssp. lactis
Metabolic The Lean One
Strains: Bifidobacterium animalis ssp. lactis + Streptococcus thermophilus
Study: Stenman LK, et al. Probiotic with or without fiber controls body fat mass in overweight adults. EBioMedicine. 2016;13:190–200. PMID 27810310. pubmed.ncbi.nlm.nih.gov/27810310
Focus & Calm The Calm One
Strains: Bifidobacterium animalis ssp. lactis + Limosilactobacillus reuteri
Study: Billeci L, et al. Effects of probiotics on electroencephalography in preschoolers with autism. Autism. 2023;27(3):814–827. PMID 35362336. pubmed.ncbi.nlm.nih.gov/35362336
Women's The Radiant One
Strains: Lactobacillus gasseri + Lactobacillus fermentum
Study: Tomusiak A, et al. Efficacy and safety of a vaginal probiotic product containing L. fermentum + L. gasseri. Drug Des Devel Ther. 2015;9:5345–5354. PMID 26451088. pubmed.ncbi.nlm.nih.gov/26451088
Boosters — Tolerability
These are complaint / tolerability rates, not efficacy. Overall baseline complaint rate: 4.87% (n=18,383).
| Booster | Type | Complaint rate | Target |
|---|---|---|---|
| Clear Skin (botanical) | Botanical booster | 4.0% | Skin |
| Digest Ease | Personalized booster | 4.3% | GI motility |
| Metabolic Fire | Personalized booster | 4.5% | Metabolic |
| Anti-Inflammatory (botanical) | Botanical booster | 5.1% | Systemic |
| Defense Plus | Personalized booster | 5.5% | Immune |
| Joint Ease | Personalized booster | 5.7% | Joint |
| Gut Seal | Personalized booster | 5.9% | Barrier |
| Mood Lift | Personalized booster | 6.0% | Mood |
| Skin Glow | Personalized booster | 6.2% | Skin |
| Stress Shield | Personalized booster | 6.3% | Stress |
| Focus Fuel | Personalized booster | 6.8% | Cognitive |
| Flora Balance | Personalized booster | 9.8% | Vaginal pH |
Methodology
Figures are drawn from a paired real-world cohort (n=651; 1,379 symptom-instances) tracked across ~6.6-month median intervals and followed longitudinally out to 20 months, a tolerability cohort (n=18,383), and a sequencing cohort (n=14,704). Analyses used McNemar's test with Benjamini–Hochberg FDR correction. This is real-world evidence, not a controlled trial.
Peer-Reviewed Publication
Phan J, Calvo DC, Nair D, Jain S, Montagne T, Dietsche S, Blanchard K, Treadwell S, Adams J, Krajmalnik-Brown R. Precision synbiotics increase gut microbiome diversity and improve gastrointestinal symptoms in a pilot open-label study for autism spectrum disorder. mSystems. 2024;9(5):e00503-24. PMID 38661344. doi.org/10.1128/msystems.00503-24
Conducted in collaboration with Arizona State University. A pilot open-label study (not a randomized controlled trial) — we say so plainly.
Foundational References
- Hill C, et al. ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
- Sanders ME, et al. Probiotics and prebiotics in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(10):605–616.
References
- Martoni CJ, et al. Impact of a probiotic product on bowel habits in functional constipation. J Dig Dis. 2019;20(9):478–487. PMID 31271261. pubmed.ncbi.nlm.nih.gov/31271261
- Hidalgo-Cantabrana C, et al. Lactiplantibacillus plantarum HEAL9 improves cognition in moderately stressed subjects. Nutrients. 2023;15(15):3466. PMID 37571403. pubmed.ncbi.nlm.nih.gov/37571403
- Leyer GJ, et al. Probiotic effects on cold and influenza-like symptom incidence in children. Pediatrics. 2009;124(2):e172–179. PMID 19651563. pubmed.ncbi.nlm.nih.gov/19651563
- Stenman LK, et al. Probiotic with or without fiber controls body fat mass in overweight adults. EBioMedicine. 2016;13:190–200. PMID 27810310. pubmed.ncbi.nlm.nih.gov/27810310
- Billeci L, et al. Effects of probiotics on electroencephalography in preschoolers with autism. Autism. 2023;27(3):814–827. PMID 35362336. pubmed.ncbi.nlm.nih.gov/35362336
- Tomusiak A, et al. Efficacy and safety of a vaginal probiotic product containing L. fermentum + L. gasseri. Drug Des Devel Ther. 2015;9:5345–5354. PMID 26451088. pubmed.ncbi.nlm.nih.gov/26451088
- Hill C, et al. ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
- Sanders ME, et al. Probiotics and prebiotics in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(10):605–616.
Press & Media
Press & media — for product samples, founder interviews, or clinical data briefings, contact support@flore.com
These statements have not been evaluated by the Food and Drug Administration. Flore products are not intended to diagnose, treat, cure, or prevent any disease.